Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antiviral and immunostimulating marine fish oil composition

A technology of immunostimulation and composition, which is applied in the direction of antiviral agents, drug combinations, allergic diseases, etc., and can solve problems such as difficult to purify and characterize pasty products, unsuitable for pharmaceutical composition components, etc.

Inactive Publication Date: 2007-11-07
辛尼克斯发展咨询有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A disadvantage of the described invention is that the salt formation process often produces pasty products that are difficult to purify and characterize (see, for example, Examples 10-14 of the cited patent specification)
The composition described in the description has an immunostimulatory effect, but still has a drawback: even the two most effective components (L-tyrosine-fatty acid and L-lysine monohydrate-fatty acid mixture) require antioxidants to stabilize
As our own tests have shown, despite the use of stabilizers, the mixture prepared according to the above patent specification is still not suitable as an ingredient of sufficiently stable pharmaceutical compositions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] Preparations in the form of capsules (coded as SIN-E3 in the table)

[0093] A mixture (362 g) of esters of omega-3-polyunsaturated fatty acids obtained from concentrated marine fish oils containing 35% by mass of 5,8,11,14,17-eicosapentaenoic acid ethyl ester (EPA B ester), and 25% by mass of 4,7,10,13,16,19-docosahexaenoic acid ethyl ester (DHA ethyl ester), at room temperature with L-lysine hydrochloride (203 g ) and zinc gluconate (30 g). A homogeneous mixture was obtained in this way, then colloidal silica gel (25 g) and lecithin (1 g) were added. After further homogenization, the substance is filled into 1000 soft capsules according to a method known per se.

Embodiment 2

[0095] Preparations in the form of capsules

[0096]All aspects are operated according to the method described in Example 1, the difference is that the mixture contained in the composition includes: 5,8,11,14,17-eicosapentaenoic acid ethyl ester (EPA ethyl ester) containing 32.8% by mass , and 22.2% by mass of omega-3-polyunsaturated fatty acid ester (362 g) of 4,7,10,13,16,19-docosahexaenoic acid ethyl ester (DHA ethyl ester), and Active ingredients and additives as described in Example 1, with the addition of selenium (1 g) incorporated into natural yeast.

Embodiment 3

[0098] Preparations in the form of capsules (coded as SIN-E2 in the table)

[0099] A mixture (362 g) of esters of omega-3-polyunsaturated fatty acids obtained from concentrated marine fish oils containing 35% by mass of 5,8,11,14,17-eicosapentaenoic acid ethyl ester (EPA B ester), and 25% by mass of 4,7,10,13,16,19-docosahexaenoic acid ethyl ester (DHA ethyl ester), at room temperature with L-lysine hydrochloride (203 g )mix. A homogeneous mixture was obtained in this way, then colloidal silica gel (25 g) and lecithin (1 g) were added. After further homogenization, the substance is filled into 1000 soft capsules according to a method known per se.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Scriptlets based extensible automated testing software allows for an extendible, scalable and simplified process of testing data messages against standards defined in some data definition language like SECS, XML, ASN1. Scriptlets written in some scripting language like Perl, TCL / TK, BeanShell, JPyton are embedded into such data definitions allowing for a way to formally express requirements of the data items associated with such scriptlets. A data definition compiler compiles such data definitions and creates a database of data messages annotated with scriptlets. When new data message is received the test software identifies which template this message corresponds to and then executes scriptlets associated with this template using the data message and / or previous messages as a context forthe scriptlets.

Description

technical field [0001] The present invention relates to a novel antiviral and immunostimulatory pharmaceutical composition. Background technique [0002] Known omega-3-polyunsaturated fatty acids, including 5,8,11,14,17-eicosapentaenoic acid (hereinafter referred to as EPA) and 4,7,10,13,16,19-di Docosahexaenoic acid (hereinafter referred to as DHA) has an antiviral effect. The conclusions of the initial in vitro experiments (see, for example, Antimicrobial Agents and Chemotherapy 12, 523 (1977)) have been tested in animals (see, for example, U.S. Patent no. 4 513 008) and clinical data (see, for example, J.of Immunology 134 , 1914 (1985) or Clin.Exp.Immunol.65, 473 (1986)) confirmed. [0003] It is also known that L-lysine can inhibit the replication of herpes simplex virus (HSV) in human cells under in vitro conditions (see J. Vact. 87, 609 (1964)). However, clinical studies have found that L-lysine has only a minimal therapeutic effect on HSV infection (see Dermatologi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/198A61K31/23A61K33/04A61K33/30A61P31/12A61P37/04
CPCA61K31/23A61K33/04A61K31/198A61K33/30A61P31/12A61P37/04A61K2300/00
Inventor J·兹贝尔奇A·杰德纳科威茨E·康泰G·奥本K·毕罗
Owner 辛尼克斯发展咨询有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com